By using the ErbB2-specific inhibitor Lapatinib and the c-Met-specific inhibitor PHA-665752, they further demonstrated that this constitutive activation of RTK signaling is necessary to the survival of CRC cells [46]. This evidence concerns the gene MET and colorectal carcinoma.